Question special
Lead Moderator

In addition to inhibitors of PARP1, the discussion of this paper also mentioned that prostate cancer tumors have been found to be responsive to platinum-based chemotherapy. I invite our authors and experts to comment on the infrequent use of this treatment in the prostate cancer setting and whether or not this treatment modality warrants much further research into targeted therapy for patients with particular genetic mutations.